Cytosorbents (CTSO) Prices 5.26M Common Share Offering at $9.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Pre-Open Movers 07/21: (NBEV) (LXRX) (OMI) Higher; (ACAD) (PIRS) (CTSO) Lower (more...)
July 21, 2020 9:30 AM EDTToday's Pre-Open Stock Movers
New Age Beverages Corporation (Nasdaq: NBEV) 55.8% HIGHER; announced that it has entered into a definitive agreement to acquire ARIIX, together with four additional companies in the e-commerce and direct selling channels. The combination will create a global firm with estimated pro forma revenues in excess of $500 million across more than 75 countries worldwide.
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) 31.4% HIGHER; announced topline data from four Phase 3 sotagliflozin studies in type 2 diabetes: SOTA-MONO, SOTA-SU, SOTA-GLIM and SOTA-INS. The... More
Cytosorbents (CTSO) Provides Q2 Financial Results, Corporate Update
July 20, 2020 4:57 PM EDTCytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, provides preliminary Q2 2020 financial highlights and a brief corporate update.
Preliminary Q2 2020 Financial... More
Cytosorbents (CTSO) Announces Proposed $40 Million Public Offering of Common Stock
July 20, 2020 4:27 PM EDTCytoSorbents Corporation (Nasdaq: CTSO) (the "Company") a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced that it has commenced a $40 million underwritten public offering... More
